Log in

NASDAQ:ORGO - Organogenesis Stock Price, Forecast & News

-0.34 (-6.95 %)
(As of 02/16/2020 02:12 PM ET)
Today's Range
Now: $4.55
50-Day Range
MA: $4.81
52-Week Range
Now: $4.55
Volume52,941 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Organogenesis Holdings Inc., a regenerative medicine company, focuses on the development, manufacture, and commercialization of solutions for the advanced wound care, and surgical and sports medicine markets primarily in the United States. The company's advanced wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for treating DFUs; PuraPly AM to address biofilm across a range of wound types; and Affinity and NuShield to address various wound sizes and types. Its surgical and sports medicine products comprise ReNu for in-office joint and tendon applications; NuCel for bony fusion in the spine and extremities; NuShield and Affinity for surgical applications in targeted soft tissue repairs; and PuraPly AM for the surgical treatment of open wounds. The company's pipeline products include TransCyte for the treatment of second- and third-degree burns; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; Novachor for the treatment of chronic and acute wounds; Gintuit for the treatment of mucogingival conditions in adults; and PuraPly XT and PuraPly MZ for the treatment of chronic and acute wounds, as well as for surgical treatment of open wounds. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician offices. The company sells its products through direct sales representatives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.

Industry, Sector and Symbol

Industry N/A
Current SymbolNASDAQ:ORGO



Sales & Book Value

Annual SalesN/A



Next Earnings Date3/9/2020 (Confirmed)
OptionableNot Optionable

Receive ORGO News and Ratings via Email

Sign-up to receive the latest news and ratings for ORGO and its competitors with MarketBeat's FREE daily newsletter.

Organogenesis (NASDAQ:ORGO) Frequently Asked Questions

What is Organogenesis' stock symbol?

Organogenesis trades on the NASDAQ under the ticker symbol "ORGO."

How were Organogenesis' earnings last quarter?

Organogenesis Holdings Inc (NASDAQ:ORGO) issued its quarterly earnings data on Tuesday, November, 12th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.13) by $0.01. The firm had revenue of $64.27 million for the quarter, compared to analyst estimates of $64 million. View Organogenesis' Earnings History.

When is Organogenesis' next earnings date?

Organogenesis is scheduled to release their next quarterly earnings announcement on Monday, March 9th 2020. View Earnings Estimates for Organogenesis.

How can I listen to Organogenesis' earnings call?

Organogenesis will be holding an earnings conference call on Monday, March 9th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

What guidance has Organogenesis issued on next quarter's earnings?

Organogenesis updated its fourth quarter 2019 IntraDay earnings guidance on Monday, January, 13th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $72.6-74.6 million, compared to the consensus revenue estimate of $70.41 million.

What price target have analysts set for ORGO?

7 equities research analysts have issued 1-year price targets for Organogenesis' stock. Their forecasts range from $9.00 to $12.00. On average, they expect Organogenesis' share price to reach $10.29 in the next twelve months. This suggests a possible upside of 126.1% from the stock's current price. View Analyst Price Targets for Organogenesis.

What is the consensus analysts' recommendation for Organogenesis?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Organogenesis in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Organogenesis.

Has Organogenesis been receiving favorable news coverage?

News headlines about ORGO stock have trended neutral recently, according to InfoTrie. The research group rates the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Organogenesis earned a news sentiment score of 0.2 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Organogenesis.

Are investors shorting Organogenesis?

Organogenesis saw a decrease in short interest in the month of January. As of January 31st, there was short interest totalling 72,400 shares, a decrease of 5.1% from the January 15th total of 76,300 shares. Based on an average daily volume of 144,800 shares, the days-to-cover ratio is currently 0.5 days. Currently, 0.7% of the shares of the company are sold short. View Organogenesis' Current Options Chain.

What other stocks do shareholders of Organogenesis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Organogenesis investors own include Opko Health (OPK), Genocea Biosciences (GNCA), Strongbridge Biopharma (SBBP), vTv Therapeutics (VTVT), Cloudera (CLDR), Aptinyx (APTX), TapImmune (MRKR), OrganiGram (OGI), Ovid Therapeutics (OVID) and AIM ImmunoTech (AIM).

Who are Organogenesis' key executives?

Organogenesis' management team includes the folowing people:
  • Mr. Gary S. Gillheeney Sr., Pres, CEO & Director (Age 64)
  • Mr. Timothy M. Cunningham, Chief Financial Officer (Age 57)
  • Mr. Patrick Bilbo, Chief Operating Officer (Age 57)
  • Ms. Lori H. Freedman, VP & Gen. Counsel (Age 52)
  • Angelyn Lowe, Director of Corp. Communications

Who are Organogenesis' major shareholders?

Organogenesis' stock is owned by a number of of retail and institutional investors. Top institutional investors include Hussman Strategic Advisors Inc. (0.21%), State Street Corp (0.17%), Bank of Montreal Can (0.12%), Charles Schwab Investment Management Inc. (0.12%), Monashee Investment Management LLC (0.12%) and K2 Principal Fund L.P. (0.09%). Company insiders that own Organogenesis stock include Alan A Ades, Arthur S Leibowitz, Avista Capital Managing Member and Michael W Katz. View Institutional Ownership Trends for Organogenesis.

Which major investors are selling Organogenesis stock?

ORGO stock was sold by a variety of institutional investors in the last quarter, including New York State Common Retirement Fund. View Insider Buying and Selling for Organogenesis.

Which major investors are buying Organogenesis stock?

ORGO stock was purchased by a variety of institutional investors in the last quarter, including Hussman Strategic Advisors Inc., Bank of Montreal Can, Monashee Investment Management LLC, K2 Principal Fund L.P., Charles Schwab Investment Management Inc., Guild Investment Management Inc., State Street Corp and Private Advisors LLC. Company insiders that have bought Organogenesis stock in the last two years include Alan A Ades, Arthur S Leibowitz, Avista Capital Managing Member and Michael W Katz. View Insider Buying and Selling for Organogenesis.

How do I buy shares of Organogenesis?

Shares of ORGO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Organogenesis' stock price today?

One share of ORGO stock can currently be purchased for approximately $4.55.

MarketBeat Community Rating for Organogenesis (NASDAQ ORGO)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  43 (Vote Outperform)
Underperform Votes:  45 (Vote Underperform)
Total Votes:  88
MarketBeat's community ratings are surveys of what our community members think about Organogenesis and other stocks. Vote "Outperform" if you believe ORGO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ORGO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/16/2020 by MarketBeat.com Staff

Featured Article: Economic Reports

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel